Hikma Pharmaceuticals

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Hikma Pharmaceuticals
Type Public company (LSEHIK)
Industry Pharmaceutical
Founded 1978
Headquarters London, UK
Key people Samih Darwazah Chairman
Said Darwazah CEO
Products Amoclan
Prograf
Suprax
Revenue US$1,365 million (2013)[1]
Operating income US$413 million (2013)[1]
Net income US$216 million (2013)[1]
Employees circa 6,000 (2012)
Website www.hikma.com

Hikma Pharmaceuticals is a multinational pharmaceutical company based in London, that manufactures branded and non-branded generic and in-licensed pharmaceutical products. It was first listed on the London Stock Exchange in 2005 and is a constituent of the FTSE 250 Index. It was founded in Jordan in 1978 by Samih Darwazah.

History[edit]

The Company was founded by Samih Darwazah in 1978 in Amman in Jordan.[2] In August 1996 it became the first Arab company to export pharmaceutical products to the United States.[3] It was first listed on the London Stock Exchange in 2005.[2] Recent acquisitions include Instituto Biochimico Pavese Pharma in Italy in 2005[4] and Jazeera Pharmaceutical Industries in Saudi Arabia in 2006.[2] In 2007 the Company went on to buy APM in Jordan,[5] Alkan Pharma in Egypt,APM and Al Jazeera Pharma in Saudi Arabia[5] Thymoorgan in Germany[2] and Ribosepharm in Germany.[2] It also acquired Multi-Source Injectables in the USA in October 2010.[6] In May 2011 Hikma Pharmaceuticals PLC complete the acquisition of Baxter Healthcare Corporation's US generic injectables business (Multi-Source Injectables or MSI).[7][8]

In 2011 the company won the ICSA / Hermes Transparency in Governance Award for the best audit disclosure for a FTSE 250 company.[9]

Operations[edit]

The Company's production facilities are located in the following countries:

See also[edit]

References[edit]

External links[edit]